Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein.
about
The great escape: viral strategies to counter BST-2/tetherinOrigins of HIV and the AIDS pandemicThe restriction factors of human immunodeficiency virusHIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanismsThe mouse "xenotropic" gammaretroviruses and their XPR1 receptorDifferential effects of human immunodeficiency virus type 1 Vpu on the stability of BST-2/tetherinBST-2/tetherin: a new component of the innate immune response to enveloped virusesAntiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteractionThe role of BST-2/Tetherin in host protection and disease manifestationDirect restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particlesThree-Dimensional Structural Characterization of HIV-1 Tethered to Human Cells.Native immunogold labeling of cell surface proteins and viral glycoproteins for cryo-electron microscopy and cryo-electron tomography applicationsStructural and functional studies on the extracellular domain of BST2/tetherin in reduced and oxidized conformationsStructural insight into the mechanisms of enveloped virus tethering by tetherinStructural and Biophysical Analysis of BST-2/Tetherin Ectodomains Reveals an Evolutionary Conserved Design to Inhibit Virus ReleaseQuantitative multicolor super-resolution microscopy reveals tetherin HIV-1 interaction.Bone marrow stromal cell antigen 2 (BST-2) restricts mouse mammary tumor virus (MMTV) replication in vivoMechanism of HIV-1 virion entrapment by tetherinInterferon-induced tetherin restricts vesicular stomatitis virus release in neuronsHSV-2 glycoprotein gD targets the CC domain of tetherin and promotes tetherin degradation via lysosomal pathwayIntrinsic cellular defenses against human immunodeficiency virusesCounteraction of the multifunctional restriction factor tetherinVpu and BST2: Still Not There Yet?Differential sensitivities of tetherin isoforms to counteraction by primate lentiviruses.Tetherin Sensitivity of Influenza A Viruses Is Strain Specific: Role of Hemagglutinin and Neuraminidase.A tail of Tetherin: how pandemic HIV-1 conquered the world.Tetherin/BST-2: Restriction Factor or Immunomodulator?Differential Control of BST2 Restriction and Plasmacytoid Dendritic Cell Antiviral Response by Antagonists Encoded by HIV-1 Group M and O Strains.Tetherin Antagonism by HIV-1 Group M Nef Proteins.Modulation of HIV-1-host interaction: role of the Vpu accessory proteinAnalysis of the human immunodeficiency virus type 1 M group Vpu domains involved in antagonizing tetherin.Lack of adaptation to human tetherin in HIV-1 group O and P.HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.SIV replication in human cellsAnimal models for HIV/AIDS researchTetherin restricts direct cell-to-cell infection of HIV-1.Macaques as model hosts for studies of HIV-1 infectionThe C-terminal sequence of IFITM1 regulates its anti-HIV-1 activityUltra structural characterisation of tetherin - a protein capable of preventing viral release from the plasma membraneAntagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment
P2860
Q21090506-09253E9D-AED3-4A91-90F6-2FD0F8B832A6Q22242661-879EAB31-6CB5-452B-BF0C-4B15BC6C3EB4Q24605108-37CF69F9-B99E-40BD-816C-3FF364FE5268Q24619066-30D51C9D-EAAC-4083-89B6-9B331856B5DFQ24622259-9526F41B-7252-436C-93D5-3B7BE1176FA6Q24629504-51FBFBE4-762B-41B8-A019-A63F36E6DDA3Q24630382-8394F13D-61AD-44C3-9EA3-0BD5A6D3BC01Q24635271-877CD784-6C80-4F15-A646-6F76F060A2C4Q26752737-CCF1C2BA-E14F-43BB-A940-CA2AB2C97DB3Q27316022-31A5FBCC-7AA6-4362-8A05-EBFB59EA9952Q27321247-E1D5EC55-7EE8-4A1F-A807-A087774FC4A3Q27335433-7C5EDDD9-089D-466D-85A5-3513C810EC6CQ27664759-42EC6339-1886-4EB8-B63D-37A62528C987Q27664987-D2F155E0-B17C-4351-A238-FC393CC1C8DCQ27665937-DD67CA53-AC8B-4B98-B492-6D4977728AA1Q28478446-D2C37C05-03B7-4285-9E29-205D82007A54Q28510187-BFA33BB3-9AB8-43C0-9E20-9CCB61F43ADCQ28534707-5CF65F81-7470-4C81-8C4D-B63B95ADDF17Q28585561-24786983-F460-4CB5-A4A9-1B4B48156E86Q28595739-52A0DAFF-30AF-4711-A3B0-8EEA93BC17B6Q28659575-F257914B-ED8C-4B4C-BD72-4B12E9174C15Q28659945-2AF72E2F-33D9-4D09-BACF-5E1F4A3A2BE4Q28730708-806EA9FF-78B5-4CFB-89BA-17E70849EA5EQ30360141-D8A1333F-5C21-4D9D-9F58-F0993A17B494Q30376050-FC3C105B-8B97-4C30-9381-AE420E652706Q30382586-6E3FFA69-39B8-4696-A98F-281E7CECED35Q30385433-8D2251DD-F36F-4703-9052-72146F5E2FB9Q30392459-5EF4DF49-C28B-4639-A71E-3D5EC7632AC8Q30393226-F4CA45D2-50BF-4CF5-9BF2-60A6B6B3F642Q30397761-12EF45AB-5D49-44D7-9C35-5C4FC5A5B2CDQ30406836-AE0519DA-359B-4EAC-9F07-0F88D3FD42D4Q30407564-F89A8ADA-C29A-4F0A-9676-2CB5FC9DC027Q30410687-3AA90C9F-FFAC-49C2-B928-B7BBA5B61917Q30417737-356573B0-9801-4F09-B82B-04EDD5403FC7Q30423656-587B332A-EF96-488C-8E58-D5FF2C879197Q30497822-E0D90609-00ED-4F9F-BF93-F5EAB673BA74Q30653348-3A36C6AF-961F-489E-BB75-3502B706E314Q30973896-888CF932-054B-4323-B048-CA3F081D14E2Q31034125-92527A46-AAFD-457D-8092-ED1EAD77ED55Q33553369-D0730E88-481C-40DE-BE58-493B1DC29747
P2860
Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Antagonism to and intracellula ...... type 2 envelope glycoprotein.
@en
Antagonism to and intracellula ...... type 2 envelope glycoprotein.
@nl
type
label
Antagonism to and intracellula ...... type 2 envelope glycoprotein.
@en
Antagonism to and intracellula ...... type 2 envelope glycoprotein.
@nl
prefLabel
Antagonism to and intracellula ...... type 2 envelope glycoprotein.
@en
Antagonism to and intracellula ...... type 2 envelope glycoprotein.
@nl
P2860
P356
P1433
P1476
Antagonism to and intracellula ...... type 2 envelope glycoprotein.
@en
P2093
Anna Le Tortorec
Stuart J D Neil
P2860
P304
11966-11978
P356
10.1128/JVI.01515-09
P407
P577
2009-09-09T00:00:00Z